Table 1.

Clinical parameters for patients with pamidronate-associated FSGSa

ParameterPatientPatientPatientPatientPatientPatientPatient
1234567
aM, male; F, female; C, Caucasian; MM, multiple myeloma; Br Ca, carcinoma of breast; HD, hemodialysis; FSGS, focal segmental glomerulosclerosis; NA, not available.
bPatient 7 never received >60 mg/mo of pamidronate.
cBefore pamidronate administration.
dPatient 2 began to undergo dialysis immediately after biopsy.
Age (yr)63715053497677
GenderMFFFFFM
RaceCCCCCCC
Type of tumorMMMMMMMMBr CaMMMM
Oncologic treatment
total-body irradiationYesNoNoNoNoNoNo
cisplatinYesYesNoNoNoNoNo
pamidronateYesYesYesYesYesYesYes
time (mo) at 90 mg/mo98184161548b
time (mo) at >90 mg/mo8122421900
maximal dosage (mg/mo)3603603601801809060
Baseline serum creatinine concentration (mg/dl)c1.21.20.5“Normal”0.61.21.2
Renal status at biopsy
serum creatinine concentration (mg/dl)44.22.834.851.6
24-h urinary protein excretion (g/d)26125.814.81585.4
serum albumin concentration (g/dl)2.72.32.82.51.93.63.5
serum cholesterol concentration (mg/dl)NA388NA725521334NA
peripheral edemaYesYesYesYesYesYesYes
full nephrotic syndromeYesYesYesYesYesYesYes
Length of postbiopsy follow-up period (mo)10d37513
final serum creatinine concentration (mg/dl)8.4/HDHD7.5/HD4.34.28/HD1.4
pamidronate continuedYesNoYesNoNoNoNo
additional therapyNoneNoneNoneSteroidsSteroidsSteroidsNone